Skip to main content Deutsch


Karsten Bamminger
Karsten Bamminger, MSc

Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: PHD Student

ORCID: 0000-0003-3811-7485


Biomarkers, Pharmacological; Positron-Emission Tomography; Programmed Cell Death 1 Receptor

Research group(s)

Research interests

My research focuses primarily on the development of PET tracers for the PD-1/PD-L1 immune checkpoint. The ultimate goal is to achieve a better patient stratifcation in the context of anti-cancer immunotherapy and to improve therapy respone and survial.

Selected publications

  1. Bamminger, K. et al. (2023) ‘On the Road towards Small-Molecule Programmed Cell Death 1 Ligand 1 Positron Emission Tomography Tracers: A Ligand-Based Drug Design Approach’, Pharmaceuticals, 16(7), p. 1051. Available at:
  2. Bamminger, K. et al. (2022) ‘Rapid, high-yield enzymatic synthesis of n.c.a. 6-[18F]fluorodopamine (6-[18F]FDA) for in vivo application’, Nuclear Medicine and Biology, 114–115, pp. 189–197. Available at:
  3. Pichler, V. et al. (2019) ‘Pitfalls and solutions of the fully-automated radiosynthesis of [11C]metoclopramide’, EJNMMI Radiopharmacy and Chemistry, 4(1). Available at:
  4. Bauer, M. et al., 2021. Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide. Molecular Imaging and Biology, 23(2), pp.180–185. Available at:
  5. Bauer, M. et al., 2020. Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology & Therapeutics, 109(3), pp.754–761. Available at: